Baricitinib-d3
Baricitinib-d3 is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.
Product Specifications
CAS Number
1564242-30-3
Product Name Alternative
LY3009104-d3; INCB028050-d3
UNSPSC
12352005
Target
JAK
Type
Isotope-Labeled Compounds
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Inflammation/Immunology
Purity
99.0
Solubility
10 mM in DMSO
Smiles
N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC([2H])([2H])[2H])=O)C1
Molecular Formula
C16H14D3N7O2S
Molecular Weight
374.44
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184 (9) :5298-307.|[3]Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2 (4) :351-5.|[4]Khan IM, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration resistance. Int J Obes (Lond) . 2015 Nov;39 (11) :1607-18.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC741003-500 1x 500 µL
Mucin 5AC (MUC5AC) (58M1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740029-500 1x 500 µL
Fibronectin (TV-1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details